AJP Asia Intelligence Agency

HLB and HLB Life Science Revive Merger Plans, Targeting Completion by June


HLB and HLB Life Science are reviving their merger plans that were previously abandoned last year. This decision aims to integrate business capabilities from new drug development to approval and commercialization, while enhancing management efficiency.

On the 19th, HLB and HLB Life Science held board meetings and announced that HLB has approved the plan to absorb HLB Life Science. The two companies plan to consolidate their dispersed business capabilities and management resources in line with the expansion of their new drug business from research and development (R&D) to commercialization.

The merger will proceed by issuing new HLB shares to HLB Life Science shareholders. The merger price per share is set at 30,063 won (KRW) for HLB and 2,578 won (KRW) for HLB Life Science, with 0.0857532 shares of HLB common stock allocated for each share of HLB Life Science common stock.
 
Through this merger, HLB will integrate the exclusive domestic development and sales rights of Rivosertan held by HLB Life Science, as well as the revenue-sharing rights in Japan and Europe. The plan aims to simplify the rights structure related to new drugs and improve decision-making efficiency during the development and commercialization processes.

HLB intends to combine its existing new drug development and global commercialization capabilities with the research and development personnel and resources of HLB Life Science. The medical supplies business of HLB Life Science, including syringes, will also be expanded through cross-selling with HLB's healthcare business and distribution network to generate new revenue. The companies will streamline their dispersed management support functions and internal transaction structures to achieve cost reductions.

Previously, the two companies attempted a merger last year to integrate new drug development capabilities and enhance management efficiency, but withdrew when the stock buyback amount exceeded the merger contract's cancellation threshold of 40 billion won (KRW). 

During the merger process, both companies will establish a special committee composed of three independent directors and review the feasibility and transaction conditions of the merger through consultations and evaluations by external experts. They plan to communicate with shareholders through shareholder meetings and a Q&A section on their website.

Once the merger is completed, HLB will maintain its status as a listed entity on KOSDAQ and will generally inherit the existing business, assets, liabilities, contractual rights, and obligations of HLB Life Science. The two companies aim to complete the merger by June 30 of next year, following the necessary procedures.

An HLB official stated, "This merger is a strategic decision to integrate the new drug development capabilities and business foundations of both companies to establish a management system optimized for new drug commercialization. We will maximize synergies between businesses and enhance management efficiency to strengthen competitiveness."

Meanwhile, HLB Group has also established a new future strategy organization and conducted a reorganization that promotes a significant number of executives in their 40s.





* This article has been translated by AI.